MentionFox
Home › Executive changes › Actinium Pharmaceuticals, Inc.
Leadership changes · ATNM · SEC Form 8-K, Item 5.02

Leadership changes at Actinium Pharmaceuticals, Inc. (2026)

Before you join, sell to or invest in Actinium Pharmaceuticals, Inc.

MentionFox check on Actinium Pharmaceuticals, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/actinium-pharmaceuticals

Check Actinium Pharmaceuticals, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Actinium Pharmaceuticals, Inc.?

Who joined and who left Actinium Pharmaceuticals, Inc. (ATNM)? 2 appointments reported on 2026-02-13, each cited to the company's own filing.

Sandesh Seth was named Chief Executive Officer of Actinium Pharmaceuticals, Inc. As of November 14, 2026, Actinium Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 13, 2026, naming 2 appointments (Form 8-K, February 13, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Sell to companies like Actinium Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)2
Latest filing2026-02-13

Actinium Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Actinium Pharmaceuticals, Inc. files it.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-13InChief Executive Officer8-K, 2026-02-13
2026-02-13In8-K, 2026-02-13

Selling to them or working with them? See who runs Actinium Pharmaceuticals, Inc. now and the warning signs.

Watch Actinium Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Want the whole picture on Actinium Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Actinium Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Actinium Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Who leads Actinium Pharmaceuticals, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Actinium Pharmaceuticals, Inc.?

New leaders reset buying decisions — get the Full Report on Actinium Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Actinium Pharmaceuticals, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Executive Officer at Actinium Pharmaceuticals, Inc., with the record behind each one.

Find candidates like Chief Executive Officer at Actinium Pharmaceuticals, Inc.

Every change, in the filing's words

Filed 2026-02-13 · 8-K

Appointed: Sandesh Seth, Chief Executive Officer

Additionally, on February 13, 2026, to fill the executive vacancy as a result of Mr. O'Loughlin's resignation as the principal financial officer of the Company, the Board appointed Sandesh Seth, the current Chairman and Chief Executive Officer of the Company, to serve as the principal financial officer, effective as of the Effective Date.

Appointed: Sandesh Seth

Mr. Seth was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations.

Also stated in this filing

  • Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
  • On February 11, 2026, Steve O'Loughlin tendered his resignation as the Chief Financial Officer of Actinium Pharmaceuticals, Inc. (the "Company"), effective as of February 27, 2026, to pursue other opportunities (the "Effective Date").
  • There were no disagreements with the Company that contributed to Mr. O'Loughlin's resignation.
  • Mr. Sandesh Seth has been the Chief Executive Officer of the Company since June 2017.
  • Mr. Seth has been a Director since March 2012, the Company's Chairman of the Board since October 2013, and served as Executive Chairman from August 2014 to June 2017.
  • Mr. Seth has 25 plus years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management).
  • Mr. Seth was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found.
  • Mr. Seth has an MBA in Finance from New York University, an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University.

Tools for this story

Each opens in a new tab, filled in for Actinium Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/actinium-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing
Actinium Pharmaceuticals, Inc. names Sandesh Seth CEO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/actinium-pharmaceuticals